Publications by the researcher in collaboration with Javier Crespo García (15)

2024

  1. Letter to the Editor: Serum Identification of At-Risk MASH: The Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF)

    Hepatology

  2. Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)

    Hepatology, Vol. 79, Núm. 1, pp. 135-148

  3. The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis

    Journal of Gastroenterology, Vol. 59, Núm. 7, pp. 586-597

2022

  1. Global multi-stakeholder endorsement of the MAFLD definition

    The Lancet Gastroenterology and Hepatology

  2. Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles

    Hepatology, Vol. 76, Núm. 4, pp. 1121-1134

2021

  1. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects

    Liver International, Vol. 41, Núm. 9, pp. 2076-2086

  2. E2F1 and E2F2-mediated repression of CPT2 establishes a lipid-rich tumor-promoting environment

    Cancer Research, Vol. 81, Núm. 11, pp. 2874-2887

  3. Immune Checkpoint Inhibitors: The Emerging Cornerstone in Cholangiocarcinoma Therapy?

    Liver Cancer, Vol. 10, Núm. 6, pp. 545-560

  4. Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis

    Molecular Metabolism, Vol. 53

2020

  1. Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis

    Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 1, pp. 216-225.e5

  2. Erratum to: “Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17–25) (Journal of Hepatology (2020) 73(1) (17–25), (S0168827820301276), (10.1016/j.jhep.2020.02.028))

    Journal of Hepatology

  3. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH

    Journal of Hepatology, Vol. 73, Núm. 1, pp. 17-25

2018

  1. Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts

    Hepatology Communications, Vol. 2, Núm. 7, pp. 807-820

  2. MiR-873-5p acts as an epigenetic regulator in early stages of liver fibrosis and cirrhosis

    Cell Death and Disease, Vol. 9, Núm. 10

  3. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity

    Alimentary Pharmacology and Therapeutics, Vol. 48, Núm. 11-12, pp. 1260-1270